Building Bone: Next-Generation Osteoporosis Therapies
This article was originally published in Start Up
Executive Summary
As Amgen gears up to launch osteoporosis candidate denosumab, a host of smaller players are working on what they see as the next-generation therapies: those that help build up new bone. Tough economic times across the board, plus the high development risks and costs associated with osteoporosis--a chronic, primary care condition--are making financing almost impossible for some.
You may also be interested in...
Best of the Blog, START-UP July-August 2009
A rundown of our favorite blog posts from July and August on stories not covered elsewhere in this issue of Start-Up. (See the original postings for free at http://invivoblog.blogspot.com/).
Best of the Blog, START-UP July-August 2009
A rundown of our favorite blog posts from July and August on stories not covered elsewhere in this issue of Start-Up. (See the original postings for free at http://invivoblog.blogspot.com/).
Amgen's D-mab: The New EPO
D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.